4.7 Article

Defining imaging biomarker cut points for brain aging and Alzheimer's disease

Journal

ALZHEIMERS & DEMENTIA
Volume 13, Issue 3, Pages 205-216

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.08.005

Keywords

Alzheimer's disease; Alzheimer's imaging; Alzheimer's MRI; Amyloid PET; Tau PET; FDG PET; Alzheimer's biomarkers; Quantitative imaging

Funding

  1. National Institute of Health [R01 AG011378, R01 AG041851, U01 AG006786, R01 AG034676]
  2. GHR Foundation
  3. Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation

Ask authors/readers for more resources

Introduction: Our goal was to develop cut points for amyloid positron emission tomography (PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods: We examined five methods for determining cut points. Results: The reliable worsening method produced a cut point only for amyloid PET. The specificity, sensitivity, and accuracy of cognitively impaired versus young clinically normal (CN) methods labeled the most people abnormal and all gave similar cut points for tau PET, FDG PET, and cortical thickness. Cut points defined using the accuracy of cognitively impaired versus age-matched CN method labeled fewer people abnormal. Discussion: hi the future, we will use a single cut point for amyloid PET (standardized uptake value ratio, 1.42; centiloid, 19) based on the reliable worsening cut point method. We will base lenient cut points for tau PET, FDG PET, and cortical thickness on the accuracy of cognitively impaired versus young CN method and base conservative cut points on the accuracy of cognitively impaired versus age-matched CN method. (C) 2016 The Authors. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available